AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy for 2027?
AbbVie reported FY 2025 revenue of about $61.2 billion, up roughly 8.6% year over year. [[fact:fact-4gvtj6rto]] Bristol Myers Squibb reported FY 2025 revenue of about $48.2 billion, down 0.2% year over year. [[fact:fact-95u3rgr2o]] Skyrizi and Rinvoq together accounted for roughly 42% of AbbVie's total net revenue in 2025. [[fact:fact-hoa1rnq6p]] The article forecasts Bristol Myers Squibb's current fiscal-year revenue to rise 3% to $49.9 billion, but this projection is unconfirmed. [[fact:fact-pagal02qc]] It also forecasts Bristol Myers Squibb's net income to rise more than 40% to $11.2 billion, another unconfirmed projection. [[fact:fact-vqlcrohbl]] Bristol Myers Squibb faces a revived $6.7 billion lawsuit related to its Celgene acquisition. [[fact:fact-byyh3ckyl]]